Pulmonary Embolism

Clinical Trial Finder

Many patients with pulmonary embolism are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Study of the Etiology and Immunological Pathogenesis in Acute Exacerbation of Idiopathic Pulmonary Fibrosis (AE-IPF)

Condition:   Interstitial Lung Diseases
Intervention:   Other: No intervention
Sponsor:   Shanghai Pulmonary Hospital, Shanghai, China
Enrolling by invitation - verified July 2015

Prospective Record Of the Use of Dabigatran in Patients With Acute Stroke or TIA

Conditions:   Brain Ischemia With Non-valvular Atrial Fibrillation;   Transient Ischemic Attack With Non-valvular Atrial Fibrillation
Sponsor:   University Hospital, Essen
Recruiting - verified July 2015

XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis

Conditions:   Pulmonary Embolism;   Venous Thrombosis
Interventions:   Drug: rivaroxaban;   Drug: warfarin
Sponsors:   University of Kentucky;   Janssen Scientific Affairs, LLC
Not yet recruiting - verified July 2015

Soluble Fibrin for Diagnosing Pulmonary Embolism

Condition:   Pulmonary Embolism (PE)
Intervention:   Other: Soluble Fibrin
Sponsors:   Diagnostica Stago R&D;   European Georges Pompidou Hospital
Recruiting - verified July 2015

FFP Versus PCC in Intracranial Hemorrhage

Conditions:   Intracranial Hemorrhage, Traumatic;   Intracranial Hemorrhage, Spontaneous
Interventions:   Drug: Four Factor Prothrombin Complex Concentrate;   Biological: Fresh Frozen Plasma
Sponsor:   University of Utah
Recruiting - verified April 2015

Pharmacoepidemiology Treatment of Symptomatic Pulmonary Embolism in Hospitalized Patients Aged 75 Years or More: PEAGE

Conditions:   Elderly;   Pulmonary Embolism;   Anticoagulants
Intervention:   Other: 4 blood samples
Sponsors:   Centre Hospitalier Universitaire de Saint Etienne;   Ministry of Health, France
Recruiting - verified July 2015

Safety and Efficacy Study of Apixaban to Prevent Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With PEG Asparaginase

Conditions:   Lymphoma;   Acute Lymphoblastic Leukemia
Interventions:   Drug: Apixaban;   Other: No systemic anticoagulant prophylaxis
Sponsor:   Bristol-Myers Squibb
Recruiting - verified April 2015

Comparison of Antithrombotic Treatments After Aortic Valve Replacement. Rivaroxaban: A New Antithrombotic Treatment for Patients With Mechanical Prosthetic Aortic Heart Valve.

Conditions:   Aortic Valve Disease;   Heart Valve Prosthesis Implantation;   Anticoagulants
Intervention:   Drug: Rivaroxaban
Sponsor:   University Hospital Inselspital, Berne
Recruiting - verified July 2015

Cancer Venous Thromboembolism (VTE)

Conditions:   Venous Thromboembolism (VTE);   Deep Vein Thrombosis (DVT);   Pulmonary Embolism (PE);   Cancer
Interventions:   Drug: edoxaban;   Drug: Dalteparin
Sponsor:   Daiichi Sankyo Inc.
Recruiting - verified July 2015

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

Conditions:   Pulmonary Embolism;   Thromboembolism;   Thrombosis;   Venous Thrombosis;   Venous Thromboembolism
Interventions:   Drug: BAY 59-7939;   Drug: BAY 59-7939;   Drug: ASA
Sponsor:   Bayer
Recruiting - verified July 2015

Cook IVC Filter Study

Condition:   Pulmonary Embolism
Intervention:   Device: Günther Tulip® Vena Cava Filter and Cook Celect® Vena Cava Filters
Sponsor:   Cook
Recruiting - verified March 2015

Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer

Conditions:   Rivaroxaban;   Cancer-associated Thrombosis;   Recurrence;   Bleeding
Intervention:   Drug: Rivaroxaban
Sponsors:   Seoul National University Hospital;   Korean Society of Hematology Thrombosis Working Party
Recruiting - verified July 2015

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Phenprocoumon
Sponsor:   Bayer
Recruiting - verified July 2015

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Acenocoumarol
Sponsor:   Bayer
Recruiting - verified July 2015

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Warfarin
Sponsor:   Bayer
Recruiting - verified July 2015

Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery

Condition:   Anticoagulation
Intervention:   Drug: Apixaban
Sponsors:   Bristol-Myers Squibb;   Pfizer
Active, not recruiting - verified July 2015

Vascular Events In Surgery patIents cOhort evaluatioN - Cardiac Surgery

Conditions:   Vascular Death;   Myocardial Infarction;   Stroke;   Cardiac Surgery
Sponsors:   Population Health Research Institute;   Abbott Diagnostics Division
Recruiting - verified July 2015

A Prospective, Multi-Center Study of the Bard® Denali™ Retrievable Inferior Vena Cava Filter System

Condition:   Pulmonary Embolism
Intervention:   Device: Denali inferior vena cava filter
Sponsor:   C. R. Bard
Active, not recruiting - verified July 2015

VenaTech Convertible Vena Cava Filter U.S. Multi-Center Clinical Trial

Condition:   Pulmonary Embolism
Interventions:   Device: VenaTech Convertible Vena Cava Filter;   Procedure: Vena Cava Filter Conversion
Sponsors:   B. Braun Interventional Systems, Inc;   Bright Research Partners;   NAMSA
Active, not recruiting - verified July 2015

Erythropoietin in Traumatic Brain Injury (EPO-TBI)

Condition:   Traumatic Brain Injury
Interventions:   Drug: Epoetin Alfa;   Drug: Sodium Chloride 0.9%
Sponsors:   Australian and New Zealand Intensive Care Research Centre;   National Health and Medical Research Council, Australia;   Australian and New Zealand Intensive Care Society Clinical Trials Group;   Monash University
Completed - verified July 2015

Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma

Conditions:   DS Stage I Plasma Cell Myeloma;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
Interventions:   Drug: Clarithromycin;   Drug: Dexamethasone;   Drug: Lenalidomide
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Active, not recruiting - verified July 2015

SHORTness of Breath In the Emergency Department (SHORTIE)

Conditions:   Acute Myocardial Infarction;   Heart Failure;   Pulmonary Embolism
Intervention:   Device: Triage Profiler S.O.B. Panel
Sponsor:   Biosite
Completed - verified July 2015

Get CardioSmart

You're Invited